CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs)

被引：0

作者：

Albiges, Laurence

Schmidinger, Manuela

Pioger, Naila Taguieva

Perol, David

Gruenwald, Viktor

机构：

[1] Univ Paris Saclay, Med Oncol, Villejuif, France

[2] Med Univ Vienna, Vienna, Austria

[3] Ipsen Pharma, Boulogne, France

[4] Ctr Leon Berard, Dept Clin Res, Lyon, France

[5] Hannover Med Sch, Dept Hematol Hemostaseol Oncol & Stem Cell Transp, Hannover, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS772

引用

页数：2

共 50 条

[1] Cabopoint: a phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
Ivanyi, P.
Albiges, L.
Schmidinger, M.
Taguieva-Pioger, N.
Perol, D.
Gruenwald, V
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 274 - 274
[2] CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
Albiges, L.
Schmidinger, M.
Taguieva-Pioger, N.
Perol, D.
Gruenwald, V.
ANNALS OF ONCOLOGY, 2020, 31 : S608 - S609
[3] CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma
Albiges, Laurence
Schmidinger, Manuela
Taguieva-Pioger, Naila
Perol, David
Grunwald, Viktor
Guemas, Eric
FUTURE ONCOLOGY, 2022, 18 (08) : 915 - 925
[4] CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).
Albiges, Laurence
Powles, Thomas
Sharma, Anand
Venugopal, Balaji
Bedke, Jens
Dutailly, Pascale
Qvick, Bryan
Martin-Couce, Lidia
Perrot, Valerie
Grunwald, Viktor
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[5] Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Finn, Richard S.
Kang, Yoon-Koo
Mulcahy, Mary
Polite, Blase N.
Lim, Ho Yeong
Walters, Ian
Baudelet, Christine
Manekas, Demetrios
Park, Joong-Won
CLINICAL CANCER RESEARCH, 2012, 18 (07) : 2090 - 2098
[6] Open-label phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (mRCC)
Agarwala, S. S.
Wang, J.
Ye, D.
Sallo, V.
Stergiopoulos, S. G.
Brechenmacher, T.
Motzer, R. J.
BJU INTERNATIONAL, 2012, 110 : 15 - 15
[7] Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations
Narang, Arshit
Gebrael, Georges
Jo, Yeonjung
Thomas, Vinay Mathew
Li, Haoran
Fortuna, Gliceida Galarza
Sayegh, Nicolas
Tandar, Clara
Tripathi, Nishita
Chigarira, Beverly
Srivastava, Ayana
Chehade, Chadi Hage
Nordblad, Blake
Maughan, Benjamin L.
Agarwal, Neeraj
Swami, Umang
KIDNEY CANCER, 2024, 8 (01) : 135 - 142
[8] Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
McDermott, David F.
Lee, Jae-Lyun
Bjarnason, Georg A.
Larkin, James M. G.
Gafanov, Rustem A.
Kochenderfer, Mark D.
Jensen, Niels Viggo
Donskov, Frede
Malik, Jahangeer
Poprach, Alexandr
Tykodi, Scott S.
Alonso-Gordoa, Teresa
Cho, Daniel C.
Geertsen, Poul F.
Climent Duran, Miguel Angel
DiSimone, Christopher
Silverman, Rachel Kloss
Perini, Rodolfo F.
Schloss, Charles
Atkins, Michael B.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (09) : 1020 - 1028
[9] THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING CABOZANTINIB AS SECOND-LINE THERAPY FOR ADULT PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN RUSSIA
Krysanova, V
Krysanov, I
Ermakova, V
VALUE IN HEALTH, 2020, 23 : S448 - S448
[10] Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma
Xie, Mian
He, Chaosheng
Huang, Jinkun
Lin, Qizhan
Zou, Lixin
ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102

← 1 2 3 4 5 →